TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06130553: PRIMROSE: A Modular Phase I/IIa, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, a MTA Cooperative PRMT5 Inhibitor, as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced/Me

Sponsor: AstraZeneca · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 334 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$6,086,850

Rescue Site Savings

+$4,005,540

Unlock Full NCT06130553 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06130553 Rescue Dossier →